ERBB2 and breast carcinoma: T-DM1 + Neratinib: The FB-10 study (NCT02236000) is a phase Ib/II trial designed to assess the dose-limiting effects and efficacy of combining T-DM1 with neratinib in patients with metastatic HER2-positive breast cancer: